IL6 and liver cancer: Studies of miR-375 among liver cancers have demonstrated that this resistance may function through modulation of Non-SMC Condensin II Complex Subunit G2 (NCAPG2), Interleukin 6 (IL-6) and Transforming growth factor-beta (TGF-β) [34,35].